🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to the most inspiring mentor and for changing so many lives through your journey. Eduardo Zimmer 🦋 🚀🧠

Proudly #AlzFunded and incredibly excited for today’s program. #EndALZ Zimmer Lab Alzheimer's Association

Can’t wait!

PREVENTION!

The best part of the year is over! Can’t wait for the next AAIC #AAIC25 in Canada. Hope to see you all there again!

During my first ISTAART advisory council meeting, it was clear that everyone was sad that Paulo Caramelli was leaving, though happy that Claire Sexton , Oz Ismail Suvarna Alladi and #Zetterberg were leading the council. I am incredibly thankful for this opportunity

We are pleased to welcome these distinguished researchers and clinicians into the ISTAART Advisory Council (IAC)! Excited to work with them and the rest of the Council to set ISTAART's direction over the next 2 years. See the full IAC at istaart.alz.org/about#IAC

There is something interesting in targeting neuroinflammation in Alzheimer’s - potential indications for other diseases thelancet.com/journals/eclin…

Palestra incrível do leandro minozzo sobre a política nacional de cuidado integral a pessoas com doença de Alzheimer e outras demências. Muita coisa boa para celebrar! Eduardo Zimmer 🦋 e #nitrini em foco

Precision brain health can evolve by integrating computational frameworks of brain clocks + multimodal diversity, showing how inequities and exposomes impact brain health. Out in Nature Medicine, written with editors & the great Sandra Báez + Wyllians Borelli 👉doi.org/10.1038/s41591…

Today, Academia Brasileira de Neurologia - ABN published guidelines for using #AlzheimersDisease biomarkers and anti-amyloid therapies in Brazil, a country with significant challenges. I am glad to have led this task force with colleagues and mentors. Articles available at Dementia & Neuropsychologia (links below)

Part of the task force that published the guidelines for the use of AD biomarkers and potential use of anti-amyloid therapies in Brazil. It was an honor to work with the greatest references in this field in Brazil

Glad to contribute with the national consensus.

It’s amazing to hear an inspiring, brilliant researcher that encourage the whole Brazilian community to keep researching.

Last week, the XXXI Brazilian Congress of Neurology took place, the largest event in this field in 🇧🇷! Organized by ABN, it gathered over 5k participants and featured 380+ presentations in Campinas. Check out highlights from Dr. Eduardo Zimmer 🦋 and Dr. Wyllians Borelli!

Wanna hear about blood-based biomarkers in LMIC and their clinical implementation? Check our webinar hosted by ISTAART PIA Real World Translation Work Group. 👇

There’s no doubt that anti-amyloid will increase health discrepancy - the discussion is about the next steps. Great discussion on Leqembi, UK, Japan and the recent European decision: alzforum.org/news/conferenc…

GLP-1 agonists seem to benefit individuals with abusive behavior - food intake, alcohol, drugs. Will it work in #AD?

Here we go! Wyllians Borelli.bsky.social See you there :)

Excited to announce this new step! 🧠